Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc.

Kemwell Biopharma, a global bio/pharmaceutical contract services company headquartered in Bangalore, India, announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C., USA.

Since its inception in 1997, Cirrus has developed expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms. It also offers stand-alone analytical services including stability studies.

Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company, said Anurag Bagaria, chairman and MD of Kemwell in a press statement. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA, and PMDA approved facilities in India and Sweden.”

Source: Kemwell Biopharma


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here